ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Multiple Sclerosis Drugs Market Research Report 2025
Published Date: August 2025
|
Report Code: QYRE-Auto-8U7177
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Multiple Sclerosis Drugs Market Insights Forecast to 2028
BUY CHAPTERS

Global Multiple Sclerosis Drugs Market Research Report 2025

Code: QYRE-Auto-8U7177
Report
August 2025
Pages:79
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Biogen
Sanofi
Novartis
TEVA
Merck KGaA
Bayer
Acorda
Mallinckrodt plc

Multiple Sclerosis Drugs Market Size

The global market for Multiple Sclerosis Drugs was valued at US$ 16560 million in the year 2024 and is projected to reach a revised size of US$ 23200 million by 2031, growing at a CAGR of 5.0% during the forecast period.

Multiple Sclerosis Drugs Market

Multiple Sclerosis Drugs Market

Multiple sclerosis (MS) is a demyelinating disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged. This damage disrupts the ability of parts of the nervous system to communicate, resulting in a range of signs and symptoms, including physical, mental, and sometimes psychiatric problems.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Multiple Sclerosis Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Multiple Sclerosis Drugs.
The Multiple Sclerosis Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Multiple Sclerosis Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Multiple Sclerosis Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Multiple Sclerosis Drugs Market Report

Report Metric Details
Report Name Multiple Sclerosis Drugs Market
Accounted market size in year US$ 16560 million
Forecasted market size in 2031 US$ 23200 million
CAGR 5.0%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
Segment by Application
  • Adults
  • Children
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Biogen, Sanofi, Novartis, Teva, Merck KGaA, Bayer, ACORDA, Mallinckrodt
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Multiple Sclerosis Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Multiple Sclerosis Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

How fast is Multiple Sclerosis Drugs Market growing?

Ans: The Multiple Sclerosis Drugs Market witnessing a CAGR of 5.0% during the forecast period 2025-2031.

What is the Multiple Sclerosis Drugs Market size in 2031?

Ans: The Multiple Sclerosis Drugs Market size in 2031 will be US$ 23200 million.

Who are the main players in the Multiple Sclerosis Drugs Market report?

Ans: The main players in the Multiple Sclerosis Drugs Market are Biogen, Sanofi, Novartis, Teva, Merck KGaA, Bayer, ACORDA, Mallinckrodt

What are the Application segmentation covered in the Multiple Sclerosis Drugs Market report?

Ans: The Applications covered in the Multiple Sclerosis Drugs Market report are Adults, Children

What are the Type segmentation covered in the Multiple Sclerosis Drugs Market report?

Ans: The Types covered in the Multiple Sclerosis Drugs Market report are Injectable Medications, Oral Medications, Others

Recommended Reports

Neurological Diseases

Autoimmune Disorders

Pharmaceutical Industry

1 Multiple Sclerosis Drugs Market Overview
1.1 Product Definition
1.2 Multiple Sclerosis Drugs by Type
1.2.1 Global Multiple Sclerosis Drugs Market Value Comparison by Type (2024 VS 2031)
1.2.2 Injectable Medications
1.2.3 Oral Medications
1.2.4 Others
1.3 Multiple Sclerosis Drugs by Application
1.3.1 Global Multiple Sclerosis Drugs Market Value by Application (2024 VS 2031)
1.3.2 Adults
1.3.3 Children
1.4 Global Multiple Sclerosis Drugs Market Size Estimates and Forecasts
1.4.1 Global Multiple Sclerosis Drugs Revenue 2020-2031
1.4.2 Global Multiple Sclerosis Drugs Sales 2020-2031
1.4.3 Global Multiple Sclerosis Drugs Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Multiple Sclerosis Drugs Market Competition by Manufacturers
2.1 Global Multiple Sclerosis Drugs Sales Market Share by Manufacturers (2020-2025)
2.2 Global Multiple Sclerosis Drugs Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Multiple Sclerosis Drugs Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Multiple Sclerosis Drugs, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Multiple Sclerosis Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Multiple Sclerosis Drugs, Product Type & Application
2.7 Global Key Manufacturers of Multiple Sclerosis Drugs, Date of Enter into This Industry
2.8 Global Multiple Sclerosis Drugs Market Competitive Situation and Trends
2.8.1 Global Multiple Sclerosis Drugs Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Multiple Sclerosis Drugs Players Market Share by Revenue
2.8.3 Global Multiple Sclerosis Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Multiple Sclerosis Drugs Market Scenario by Region
3.1 Global Multiple Sclerosis Drugs Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Multiple Sclerosis Drugs Sales by Region: 2020-2031
3.2.1 Global Multiple Sclerosis Drugs Sales by Region: 2020-2025
3.2.2 Global Multiple Sclerosis Drugs Sales by Region: 2026-2031
3.3 Global Multiple Sclerosis Drugs Revenue by Region: 2020-2031
3.3.1 Global Multiple Sclerosis Drugs Revenue by Region: 2020-2025
3.3.2 Global Multiple Sclerosis Drugs Revenue by Region: 2026-2031
3.4 North America Multiple Sclerosis Drugs Market Facts & Figures by Country
3.4.1 North America Multiple Sclerosis Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Multiple Sclerosis Drugs Sales by Country (2020-2031)
3.4.3 North America Multiple Sclerosis Drugs Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Multiple Sclerosis Drugs Market Facts & Figures by Country
3.5.1 Europe Multiple Sclerosis Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Multiple Sclerosis Drugs Sales by Country (2020-2031)
3.5.3 Europe Multiple Sclerosis Drugs Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Multiple Sclerosis Drugs Market Facts & Figures by Region
3.6.1 Asia Pacific Multiple Sclerosis Drugs Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Multiple Sclerosis Drugs Sales by Region (2020-2031)
3.6.3 Asia Pacific Multiple Sclerosis Drugs Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Multiple Sclerosis Drugs Market Facts & Figures by Country
3.7.1 Latin America Multiple Sclerosis Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Multiple Sclerosis Drugs Sales by Country (2020-2031)
3.7.3 Latin America Multiple Sclerosis Drugs Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Multiple Sclerosis Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Multiple Sclerosis Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Multiple Sclerosis Drugs Sales by Country (2020-2031)
3.8.3 Middle East and Africa Multiple Sclerosis Drugs Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Multiple Sclerosis Drugs Sales by Type (2020-2031)
4.1.1 Global Multiple Sclerosis Drugs Sales by Type (2020-2025)
4.1.2 Global Multiple Sclerosis Drugs Sales by Type (2026-2031)
4.1.3 Global Multiple Sclerosis Drugs Sales Market Share by Type (2020-2031)
4.2 Global Multiple Sclerosis Drugs Revenue by Type (2020-2031)
4.2.1 Global Multiple Sclerosis Drugs Revenue by Type (2020-2025)
4.2.2 Global Multiple Sclerosis Drugs Revenue by Type (2026-2031)
4.2.3 Global Multiple Sclerosis Drugs Revenue Market Share by Type (2020-2031)
4.3 Global Multiple Sclerosis Drugs Price by Type (2020-2031)
5 Segment by Application
5.1 Global Multiple Sclerosis Drugs Sales by Application (2020-2031)
5.1.1 Global Multiple Sclerosis Drugs Sales by Application (2020-2025)
5.1.2 Global Multiple Sclerosis Drugs Sales by Application (2026-2031)
5.1.3 Global Multiple Sclerosis Drugs Sales Market Share by Application (2020-2031)
5.2 Global Multiple Sclerosis Drugs Revenue by Application (2020-2031)
5.2.1 Global Multiple Sclerosis Drugs Revenue by Application (2020-2025)
5.2.2 Global Multiple Sclerosis Drugs Revenue by Application (2026-2031)
5.2.3 Global Multiple Sclerosis Drugs Revenue Market Share by Application (2020-2031)
5.3 Global Multiple Sclerosis Drugs Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Biogen
6.1.1 Biogen Company Information
6.1.2 Biogen Description and Business Overview
6.1.3 Biogen Multiple Sclerosis Drugs Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Biogen Multiple Sclerosis Drugs Product Portfolio
6.1.5 Biogen Recent Developments/Updates
6.2 Sanofi
6.2.1 Sanofi Company Information
6.2.2 Sanofi Description and Business Overview
6.2.3 Sanofi Multiple Sclerosis Drugs Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Sanofi Multiple Sclerosis Drugs Product Portfolio
6.2.5 Sanofi Recent Developments/Updates
6.3 Novartis
6.3.1 Novartis Company Information
6.3.2 Novartis Description and Business Overview
6.3.3 Novartis Multiple Sclerosis Drugs Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Novartis Multiple Sclerosis Drugs Product Portfolio
6.3.5 Novartis Recent Developments/Updates
6.4 Teva
6.4.1 Teva Company Information
6.4.2 Teva Description and Business Overview
6.4.3 Teva Multiple Sclerosis Drugs Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Teva Multiple Sclerosis Drugs Product Portfolio
6.4.5 Teva Recent Developments/Updates
6.5 Merck KGaA
6.5.1 Merck KGaA Company Information
6.5.2 Merck KGaA Description and Business Overview
6.5.3 Merck KGaA Multiple Sclerosis Drugs Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Merck KGaA Multiple Sclerosis Drugs Product Portfolio
6.5.5 Merck KGaA Recent Developments/Updates
6.6 Bayer
6.6.1 Bayer Company Information
6.6.2 Bayer Description and Business Overview
6.6.3 Bayer Multiple Sclerosis Drugs Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Bayer Multiple Sclerosis Drugs Product Portfolio
6.6.5 Bayer Recent Developments/Updates
6.7 ACORDA
6.7.1 ACORDA Company Information
6.7.2 ACORDA Description and Business Overview
6.7.3 ACORDA Multiple Sclerosis Drugs Sales, Revenue and Gross Margin (2020-2025)
6.7.4 ACORDA Multiple Sclerosis Drugs Product Portfolio
6.7.5 ACORDA Recent Developments/Updates
6.8 Mallinckrodt
6.8.1 Mallinckrodt Company Information
6.8.2 Mallinckrodt Description and Business Overview
6.8.3 Mallinckrodt Multiple Sclerosis Drugs Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Mallinckrodt Multiple Sclerosis Drugs Product Portfolio
6.8.5 Mallinckrodt Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Multiple Sclerosis Drugs Industry Chain Analysis
7.2 Multiple Sclerosis Drugs Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Multiple Sclerosis Drugs Production Mode & Process Analysis
7.4 Multiple Sclerosis Drugs Sales and Marketing
7.4.1 Multiple Sclerosis Drugs Sales Channels
7.4.2 Multiple Sclerosis Drugs Distributors
7.5 Multiple Sclerosis Drugs Customer Analysis
8 Multiple Sclerosis Drugs Market Dynamics
8.1 Multiple Sclerosis Drugs Industry Trends
8.2 Multiple Sclerosis Drugs Market Drivers
8.3 Multiple Sclerosis Drugs Market Challenges
8.4 Multiple Sclerosis Drugs Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Biogen
Sanofi
Novartis
TEVA
Merck KGaA
Bayer
Acorda
Mallinckrodt plc
List of Tables
 Table 1. Global Multiple Sclerosis Drugs Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Multiple Sclerosis Drugs Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Multiple Sclerosis Drugs Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Multiple Sclerosis Drugs Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Multiple Sclerosis Drugs Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Multiple Sclerosis Drugs Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Multiple Sclerosis Drugs Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Multiple Sclerosis Drugs Average Price (USD/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Multiple Sclerosis Drugs, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Multiple Sclerosis Drugs, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Multiple Sclerosis Drugs, Product Type & Application
 Table 12. Global Key Manufacturers of Multiple Sclerosis Drugs, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Multiple Sclerosis Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Multiple Sclerosis Drugs as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Multiple Sclerosis Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Multiple Sclerosis Drugs Sales by Region (2020-2025) & (K Units)
 Table 18. Global Multiple Sclerosis Drugs Sales Market Share by Region (2020-2025)
 Table 19. Global Multiple Sclerosis Drugs Sales by Region (2026-2031) & (K Units)
 Table 20. Global Multiple Sclerosis Drugs Sales Market Share by Region (2026-2031)
 Table 21. Global Multiple Sclerosis Drugs Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Multiple Sclerosis Drugs Revenue Market Share by Region (2020-2025)
 Table 23. Global Multiple Sclerosis Drugs Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Multiple Sclerosis Drugs Revenue Market Share by Region (2026-2031)
 Table 25. North America Multiple Sclerosis Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Multiple Sclerosis Drugs Sales by Country (2020-2025) & (K Units)
 Table 27. North America Multiple Sclerosis Drugs Sales by Country (2026-2031) & (K Units)
 Table 28. North America Multiple Sclerosis Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Multiple Sclerosis Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Multiple Sclerosis Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Multiple Sclerosis Drugs Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Multiple Sclerosis Drugs Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Multiple Sclerosis Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Multiple Sclerosis Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Multiple Sclerosis Drugs Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Multiple Sclerosis Drugs Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Multiple Sclerosis Drugs Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Multiple Sclerosis Drugs Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Multiple Sclerosis Drugs Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Multiple Sclerosis Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Multiple Sclerosis Drugs Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Multiple Sclerosis Drugs Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Multiple Sclerosis Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Multiple Sclerosis Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Multiple Sclerosis Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Multiple Sclerosis Drugs Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Multiple Sclerosis Drugs Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Multiple Sclerosis Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Multiple Sclerosis Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Multiple Sclerosis Drugs Sales (K Units) by Type (2020-2025)
 Table 51. Global Multiple Sclerosis Drugs Sales (K Units) by Type (2026-2031)
 Table 52. Global Multiple Sclerosis Drugs Sales Market Share by Type (2020-2025)
 Table 53. Global Multiple Sclerosis Drugs Sales Market Share by Type (2026-2031)
 Table 54. Global Multiple Sclerosis Drugs Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Multiple Sclerosis Drugs Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Multiple Sclerosis Drugs Revenue Market Share by Type (2020-2025)
 Table 57. Global Multiple Sclerosis Drugs Revenue Market Share by Type (2026-2031)
 Table 58. Global Multiple Sclerosis Drugs Price (USD/Unit) by Type (2020-2025)
 Table 59. Global Multiple Sclerosis Drugs Price (USD/Unit) by Type (2026-2031)
 Table 60. Global Multiple Sclerosis Drugs Sales (K Units) by Application (2020-2025)
 Table 61. Global Multiple Sclerosis Drugs Sales (K Units) by Application (2026-2031)
 Table 62. Global Multiple Sclerosis Drugs Sales Market Share by Application (2020-2025)
 Table 63. Global Multiple Sclerosis Drugs Sales Market Share by Application (2026-2031)
 Table 64. Global Multiple Sclerosis Drugs Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Multiple Sclerosis Drugs Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Multiple Sclerosis Drugs Revenue Market Share by Application (2020-2025)
 Table 67. Global Multiple Sclerosis Drugs Revenue Market Share by Application (2026-2031)
 Table 68. Global Multiple Sclerosis Drugs Price (USD/Unit) by Application (2020-2025)
 Table 69. Global Multiple Sclerosis Drugs Price (USD/Unit) by Application (2026-2031)
 Table 70. Biogen Company Information
 Table 71. Biogen Description and Business Overview
 Table 72. Biogen Multiple Sclerosis Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 73. Biogen Multiple Sclerosis Drugs Product
 Table 74. Biogen Recent Developments/Updates
 Table 75. Sanofi Company Information
 Table 76. Sanofi Description and Business Overview
 Table 77. Sanofi Multiple Sclerosis Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 78. Sanofi Multiple Sclerosis Drugs Product
 Table 79. Sanofi Recent Developments/Updates
 Table 80. Novartis Company Information
 Table 81. Novartis Description and Business Overview
 Table 82. Novartis Multiple Sclerosis Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 83. Novartis Multiple Sclerosis Drugs Product
 Table 84. Novartis Recent Developments/Updates
 Table 85. Teva Company Information
 Table 86. Teva Description and Business Overview
 Table 87. Teva Multiple Sclerosis Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 88. Teva Multiple Sclerosis Drugs Product
 Table 89. Teva Recent Developments/Updates
 Table 90. Merck KGaA Company Information
 Table 91. Merck KGaA Description and Business Overview
 Table 92. Merck KGaA Multiple Sclerosis Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 93. Merck KGaA Multiple Sclerosis Drugs Product
 Table 94. Merck KGaA Recent Developments/Updates
 Table 95. Bayer Company Information
 Table 96. Bayer Description and Business Overview
 Table 97. Bayer Multiple Sclerosis Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 98. Bayer Multiple Sclerosis Drugs Product
 Table 99. Bayer Recent Developments/Updates
 Table 100. ACORDA Company Information
 Table 101. ACORDA Description and Business Overview
 Table 102. ACORDA Multiple Sclerosis Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 103. ACORDA Multiple Sclerosis Drugs Product
 Table 104. ACORDA Recent Developments/Updates
 Table 105. Mallinckrodt Company Information
 Table 106. Mallinckrodt Description and Business Overview
 Table 107. Mallinckrodt Multiple Sclerosis Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 108. Mallinckrodt Multiple Sclerosis Drugs Product
 Table 109. Mallinckrodt Recent Developments/Updates
 Table 110. Key Raw Materials Lists
 Table 111. Raw Materials Key Suppliers Lists
 Table 112. Multiple Sclerosis Drugs Distributors List
 Table 113. Multiple Sclerosis Drugs Customers List
 Table 114. Multiple Sclerosis Drugs Market Trends
 Table 115. Multiple Sclerosis Drugs Market Drivers
 Table 116. Multiple Sclerosis Drugs Market Challenges
 Table 117. Multiple Sclerosis Drugs Market Restraints
 Table 118. Research Programs/Design for This Report
 Table 119. Key Data Information from Secondary Sources
 Table 120. Key Data Information from Primary Sources
 Table 121. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Multiple Sclerosis Drugs
 Figure 2. Global Multiple Sclerosis Drugs Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Multiple Sclerosis Drugs Market Share by Type: 2024 & 2031
 Figure 4. Injectable Medications Product Picture
 Figure 5. Oral Medications Product Picture
 Figure 6. Others Product Picture
 Figure 7. Global Multiple Sclerosis Drugs Market Value by Application (2020-2031) & (US$ Million)
 Figure 8. Global Multiple Sclerosis Drugs Market Share by Application: 2024 & 2031
 Figure 9. Adults
 Figure 10. Children
 Figure 11. Global Multiple Sclerosis Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 12. Global Multiple Sclerosis Drugs Market Size (2020-2031) & (US$ Million)
 Figure 13. Global Multiple Sclerosis Drugs Sales (2020-2031) & (K Units)
 Figure 14. Global Multiple Sclerosis Drugs Average Price (USD/Unit) & (2020-2031)
 Figure 15. Multiple Sclerosis Drugs Report Years Considered
 Figure 16. Multiple Sclerosis Drugs Sales Share by Manufacturers in 2024
 Figure 17. Global Multiple Sclerosis Drugs Revenue Share by Manufacturers in 2024
 Figure 18. Global 5 and 10 Largest Multiple Sclerosis Drugs Players: Market Share by Revenue in Multiple Sclerosis Drugs in 2024
 Figure 19. Multiple Sclerosis Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 20. Global Multiple Sclerosis Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 21. North America Multiple Sclerosis Drugs Sales Market Share by Country (2020-2031)
 Figure 22. North America Multiple Sclerosis Drugs Revenue Market Share by Country (2020-2031)
 Figure 23. U.S. Multiple Sclerosis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 24. Canada Multiple Sclerosis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 25. Europe Multiple Sclerosis Drugs Sales Market Share by Country (2020-2031)
 Figure 26. Europe Multiple Sclerosis Drugs Revenue Market Share by Country (2020-2031)
 Figure 27. Germany Multiple Sclerosis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 28. France Multiple Sclerosis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. U.K. Multiple Sclerosis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. Italy Multiple Sclerosis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Russia Multiple Sclerosis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Asia Pacific Multiple Sclerosis Drugs Sales Market Share by Region (2020-2031)
 Figure 33. Asia Pacific Multiple Sclerosis Drugs Revenue Market Share by Region (2020-2031)
 Figure 34. China Multiple Sclerosis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. Japan Multiple Sclerosis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. South Korea Multiple Sclerosis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. India Multiple Sclerosis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. Australia Multiple Sclerosis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. Taiwan Multiple Sclerosis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Indonesia Multiple Sclerosis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Thailand Multiple Sclerosis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Malaysia Multiple Sclerosis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Philippines Multiple Sclerosis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Latin America Multiple Sclerosis Drugs Sales Market Share by Country (2020-2031)
 Figure 45. Latin America Multiple Sclerosis Drugs Revenue Market Share by Country (2020-2031)
 Figure 46. Mexico Multiple Sclerosis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Brazil Multiple Sclerosis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Argentina Multiple Sclerosis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Middle East and Africa Multiple Sclerosis Drugs Sales Market Share by Country (2020-2031)
 Figure 50. Middle East and Africa Multiple Sclerosis Drugs Revenue Market Share by Country (2020-2031)
 Figure 51. Turkey Multiple Sclerosis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. Saudi Arabia Multiple Sclerosis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. UAE Multiple Sclerosis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 54. Global Sales Market Share of Multiple Sclerosis Drugs by Type (2020-2031)
 Figure 55. Global Revenue Market Share of Multiple Sclerosis Drugs by Type (2020-2031)
 Figure 56. Global Multiple Sclerosis Drugs Price (USD/Unit) by Type (2020-2031)
 Figure 57. Global Sales Market Share of Multiple Sclerosis Drugs by Application (2020-2031)
 Figure 58. Global Revenue Market Share of Multiple Sclerosis Drugs by Application (2020-2031)
 Figure 59. Global Multiple Sclerosis Drugs Price (USD/Unit) by Application (2020-2031)
 Figure 60. Multiple Sclerosis Drugs Value Chain
 Figure 61. Channels of Distribution (Direct Vs Distribution)
 Figure 62. Bottom-up and Top-down Approaches for This Report
 Figure 63. Data Triangulation
 Figure 64. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Strategic Venue Partners

SIMILAR REPORTS

Global Multiple Sclerosis Drugs Treatment Market Insights Forecast to 2030
Global Demyelinating Diseases Therapeutics Market Research Report 2024
Global Multiple Sclerosis MS Drugs Market Research Report 2025
Drugs for Central Nervous System Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Central Nervous System Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Targeted Drugs for Multiple Sclerosis Market Research Report 2024
Central Nervous System Disorders Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Relapsing Multiple Sclerosis Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Drugs for Central Nervous System Diseases Market Insights Forecast to 2030
Central Nervous System Therapeutic Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Central Nervous System Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Relapsing Remitting Multiple Sclerosis Market Research Report 2025
Multiple Sclerosis Therapies Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Central Nervous System CNS Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Neurologic Disorders Therapeutics Market Insights Forecast to 2030
Autoimmune Disease Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Glatiramer Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Nervous System Chemicals Market Research Report 2024
Global Scleroderma Drug Market Insights Forecast to 2030
Glatiramer Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions